SCHEMBL4339175

SCHEMBL4339175

CC1=NN(c2c(F)c(F)c(C)c(F)c2F)C(=O)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.47
KMT2A Q03164 7/20 0.47
ALDH1A1 P00352 6/20 0.47
TDP1 Q9NUW8 6/20 0.47
MEN1 O00255 6/20 0.47
GAA P10253 5/20 0.47
KDM4E B2RXH2 4/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
CYP1A2 P05177 1/20 0.47
CHRM2 P08172 1/20 0.47
CYP3A4 P08684 1/20 0.47
CHRM1 P11229 1/20 0.47
TSHR P16473 1/20 0.47
PTGS1 P23219 1/20 0.47
DRD3 P35462 1/20 0.47
LMNA P02545 2/20 0.45
HTT P42858 1/20 0.45
RECQL P46063 2/20 0.44
APP P05067 7/20 0.42
PDCD1 Q15116 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7147137 0.78 MAPT (0.50) MAPTKMT2AALDH1A1TDP1MEN1
SCHEMBL17261660 0.68 MAPT (0.62) MAPTKMT2AALDH1A1TDP1MEN1
SCHEMBL3533968 0.67 KMT2A (0.60) MAPTKMT2AALDH1A1TDP1MEN1
SCHEMBL4322399 0.66 MAPT (0.65) MAPTKMT2AALDH1A1TDP1MEN1
SCHEMBL4345314 0.66 MAPT (0.64) MAPTKMT2AALDH1A1TDP1MEN1
SCHEMBL4338954 0.65 MAPT (0.65) MAPTKMT2AALDH1A1TDP1MEN1
SCHEMBL2203669 0.65 MAPT (0.77) MAPTKMT2AALDH1A1TDP1MEN1
SCHEMBL4341081 0.65 MAPT (0.62) MAPTKMT2AALDH1A1TDP1MEN1
SCHEMBL19333883 0.65 MAPT (0.57) MAPTKMT2AALDH1A1TDP1MEN1
SCHEMBL5462610 0.63 MAPT (0.72) MAPTKMT2AALDH1A1TDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130078213-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2013-03-28 US disclosed
EP-1889838-B1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-10-14 EP disclosed
EP-1889838-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2008-02-20 EP disclosed
EP-1864981-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2007-12-12 EP disclosed
US-20070129338-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION 2007-06-07 US disclosed
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US disclosed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 EP disclosed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 EP disclosed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129338-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK MAPT 4627/4885KMT2A 1838/4885ALDH1A1 1012/4885
US-20130078213-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK MAPT 4627/4885KMT2A 1838/4885ALDH1A1 1012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.